ENSC arrives at its May 13 earnings report in an unusual position: the stock is tiny, the short interest is negligible, yet borrowing its shares commands a rate that would embarrass many heavily contested names.
The standout in the data is cost to borrow. At 76% APR, it is expensive to maintain a short position in ENSC — yet the borrow market tells a story of dramatic easing. Six weeks ago, the cost ran above 170%. Since then it has more than halved, in lockstep with a collapse in short interest. Estimated short interest has fallen roughly 68% over the past month, dropping to just 1.25% of the free float. The lending pool is nowhere near stressed: availability of shares to borrow runs at over 7,000% of short interest, meaning supply is essentially unconstrained. What remains is a lingering high cost that hasn't yet caught down to the lower volume of activity.
The price chart reflects a similar story of recent pressure giving way. ENSC closed at $0.38 on May 11, down 18% over the past month and off 8% on the week — though Monday's session recovered 9%. The short score of 41, sitting in roughly the 51st percentile of the universe, does not flag any extreme positioning. The days-to-cover rank is in the 99th percentile, though that is largely a mathematical artifact of thin daily volume rather than a reflection of trapped short sellers. Availability is ample, and the borrow squeeze of earlier in the spring has demonstrably unwound.
With options data too stale to use (last meaningful reading was in late 2022) and insider trades similarly dated, the fundamental picture has to carry the weight. Estimated revenues of $7.7M sit alongside a normalised net loss of $15.3M — the profile of a pre-profitability biotech where cash runway and pipeline progress are the metrics that matter. Institutional ownership is thin and concentrated; Adage Capital added 75,000 shares in the second half of last year, the only material recent addition among the top holders. Past earnings events have been volatile in the five days following the print, with a 24% five-day decline after the November 2025 report and a roughly 8% drop after the March 2026 release.
The print will therefore test whether any progress on the pipeline or commercial development can offer a credible path toward reducing the normalised cash burn — and whether that is enough to arrest the multi-month price slide.
See the live data behind this article on ORTEX.
Open ENSC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
